PALISADE BIO, INC. Warrant Down Round Feature Increase Decrease In Equity Amount1
PALISADE BIO, INC. (PALI) reported Warrant Down Round Feature Increase Decrease In Equity Amount1 of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Shareholders' Equity
us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 · last filed 2025-03-24
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for the quarter ending 2024-12-31 was $0.00.
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for the quarter ending 2024-09-30 was $0.00.
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for the quarter ending 2023-12-31 was $0.00.
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for the quarter ending 2023-09-30 was -$16.00K.
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for fiscal 2024 was $0.00.
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for fiscal 2023 was -$16.00K.
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for fiscal 2022 was -$288.00K.
- PALISADE BIO, INC. warrant down round feature increase decrease in equity amount1 for fiscal 2021 was $0.00.
| Period end | Warrant Down Round Feature Increase Decrease In Equity Amount1 3 month | Warrant Down Round Feature Increase Decrease In Equity Amount1 6 month | Warrant Down Round Feature Increase Decrease In Equity Amount1 9 month | Warrant Down Round Feature Increase Decrease In Equity Amount1 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | $0.00 10-K · filed 2025-03-24 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$16.00K derived: sum of 2 quarters · filed 2025-03-24 | -$16.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$16.00K 10-Q · filed 2024-11-12 | -$16.00K 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | -$288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$288.00K derived: sum of 2 quarters · filed 2024-03-26 | -$288.00K 10-K · filed 2024-03-26 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |